Visgeneer Inc. (TPEX:4197)
Taiwan · Delayed Price · Currency is TWD 9.85
+0.01 (0.10%)
Feb 11, 2026, 2:51 PM CST
Visgeneer Revenue
Visgeneer had revenue of 89.95M TWD in the half year ending June 30, 2025, with 20.45% growth. This brings the company's revenue in the last twelve months to 159.76M, up 33.94% year-over-year. In the year 2024, Visgeneer had annual revenue of 115.76M, down -21.78%.
Revenue (ttm)
159.76M
Revenue Growth
+33.94%
P/S Ratio
1.86
Revenue / Employee
1.63M
Employees
98
Market Cap
297.28M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 115.76M | -32.24M | -21.78% |
| Dec 31, 2023 | 147.99M | -9.97M | -6.31% |
| Dec 31, 2022 | 157.96M | -7.32M | -4.43% |
| Dec 31, 2021 | 165.29M | -10.68M | -6.07% |
| Dec 31, 2020 | 175.96M | 23.97M | 15.77% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Taiwan Advance Bio-Pharmaceutical | 371.86M |
| TCI GENE | 324.73M |
| BioLASCO Taiwan | 277.12M |
| RBC Bioscience | 201.85M |
| NatureWise Biotech & Medicals | 180.29M |
| Feng Chi Biotech | 179.94M |
| Vectorite Biomedical | 67.90M |
| Neith | 39.35M |